| Name | Title | Contact Details |
|---|
Pathwork Diagnostics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.
Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.
Kailos Genetics, the maker of Praxis, provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions through identifying risks to common medications. Praxis is an easily accessible form of personalized medicine catered to your lifestyle.
Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.